BioCurex, Inc.(fka BOCX)

[Kag]

"BOCX said "The technology identifies a cancer marker known as RECAF(TM), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells."

Dakota,
If RECAF was truely absent in benign tumors, why in the May 16, 2006 press release did BioCurex show in the second table a comparison between cancer patients vs benign prostate conditions and RECAF's ability to distinguish between them at early and late stage of only 68%? That specific BioCurex study was done to further differentiate the stage of cancer in comparison to normal and benign prostatic growths. kag